Toxic pesticide found in tampons, say British NGOs
This finding is all the more worrying given that glyphosate is far from being the only harmful substance found in women's sanitary protection products.
Manufacturers of tampons, pads and other menstrual protection products still have a long way to go to protect the health of menstruating people.
The new report has revealed the presence of glyphosate in around 15 brands of tampons sold in the United Kingdom.
According to their investigation, concentrations of this pesticide (considered a probable human carcinogen) can be as high as 0.004 mg/kg ... 40 times the legal limit for drinking water in the UK!
One of the hypotheses put forward to explain how these substances end up in products designed for period protection is that glyphosate may have been present in certain weedkillers used in cotton fields.
In light of these findings, the NGOs behind the survey recommend that a regulatory system be put in place, along with a testing process to ensure that menstrual hygiene products are free of pesticides.
'Women, girls and people who menstruate use an average of 11,000 disposable menstrual products throughout their life.
'Despite the prolific use of these products, the potential health impacts of the chemicals and pesticides that they can contain remains largely unexamined,' says the executive summary, available on the website of Pesticide Action Network, a UK NGO that co-authored the report.
NGOs and scientists have been warning us about the toxic composition of menstrual products for several years now.
In July 2024, an American study revealed the presence of several heavy metals (arsenic, cadmium, chromium, lead and vanadium) in 24 brands of tampons sold in Europe and the United States.
Other studies were previously conducted, particularly in France.
In 2019, the magazine 60 Millions de Consommateurs sounded the alarm in a comparative test carried out to check for the presence of chemical compounds in menstrual products.
The results reported the presence of residues of several harmful substances, such as phthalates, dioxins and ... glyphosate. – AFP Relaxnews
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 days ago
- The Star
Redesigning the speculum for women's comfort
Lilium, a 3D-printed plastic alternative to the gynaecological speculum (bottom), and a traditional metal speculum (top). — Photos: AFP It is cold, hard, metallic and commonly associated with pain. No, it is not a medieval torture instrument, but the vaginal speculum, which is used every day around the world for essential gynaecological examinations. Two engineers at Delft University in the Netherlands are now rethinking the decades-old design of the speculum, long dreaded by many patients, to make it less intimidating and less painful. 'I have a lot of experience with the vaginal speculum unfortunately,' engineer Tamara Hoveling said. 'I've never seen it as a pleasurable experience and I've always wondered why it looks like this.' The PhD candidate in medical industrial design then delved into the dark history behind the creation of the speculum – one version of which was developed by American doctor James Marion Sims 180 years ago. It was 'tested on enslaved women without permission', said the 29-year-old. 'So that motivated me even more to take on this project.' Hoveling teamed up with Ariadna Izcara Gual, who was then working on her master's in industrial design engineering at Delft. 'As I was doing a lot of interviews, I was doing those sort of sketches with the same sort of shape, but people were still scared of the device,' said the 28-year-old Spanish researcher. The Cusco speculum – the most commonly-used model – is a metal device with a handle, beak and screw to adjust how wide it opens once inside the vagina. For many, its insertion is uncomfortable or even painful, and causes anxiety. 'When you get scared, your muscles clamp together and that makes it even harder to relax. 'Then the speculum is opened, pushing against these tense muscles and making it even more painful,' Hoveling said. 'So I tried to look for shapes that might be related to the reproductive organs, like, for example, the flower, that also opens.' The result was a prototype called the Lilium, named after the lily flower. Hoveling shows 3D-printed prototypes of Lilium. On the table are also metal speculums, which are the current standard equipment used for vaginal examinations. Like the more familiar tampon, it is made of soft plastic and has an applicator. 'It's designed with the patient in mind, rather than the doctor. 'And we're really trying to improve the comfort aspect in a sensitive spot.' The Lilium also meets doctors' needs. Its three-sided opening keeps the vaginal walls from collapsing, allowing better visibility during examinations. The Lilium remains at an early stage, with further ergonomic testing and material research needed to refine the prototype. The researchers must still secure safety certifications, run human trials and obtain regulatory approval before it can reach clinics. To fund the next phase, they launched a crowdfunding campaign that quickly drew media attention in the Netherlands. Within just two days, the campaign raised 100,000 euros (RM493,270), far surpassing expectations. 'It's also a sign. It's proof there are people who really want change, that there is a real problem here, and that the current market solutions are not the best,' Hoveling said. 'I've received a lot of emails from women who told me they actually don't go to the gynaecologist because of this device, because they're scared, because they have a traumatic experience.' Cervical cancer is the fourth most common cancer among women, according to the World Health Organization (WHO). It can be detected via a smear test or HPV (human papillomavirus) screening – both performed using a speculum. With funding to allow this new gynaecological tool to be developed properly, the Lilium could be saving lives within five years. – By Stéphanie Hamel/AFP
The Star
4 days ago
- The Star
More British babies born via IVF, showing changing landscape of fertility care
IVF births in Britain have increased from 1.3% in 2000 to 3.1% in 2023. Photo: Freepik The equivalent of almost one child in every classroom in Britain is now born as a result of in-vitro fertilisation or IVF fertility treatment, new figures suggest. Almost 21,000 babies were born from IVF in 2023, compared to 8,700 in 2000, the Human Fertilisation and Embryology Authority (HFEA) said. The authors of the fertility regulator's latest report wrote: "IVF births are making up a higher proportion of all British births over time, increasing from 1.3% in 2000 to 3.1% in 2023. "This means around one in 32 British births in 2023 were via IVF – roughly one child in every classroom – compared to one in 43 in 2013.' The HFEA said that its latest figures show the "changing landscape' of fertility care in Britain. Overall, 52,400 patients had ,ore than 77,500 in vitro fertilisation (IVF) cycles at British fertility clinics in 2023. Some 11% of births to women aged 40-44 were a result of IVF, increasing from 4% in 2000 and accounting for 0.5% of all births, HFEA said. The data also reveal a rise in the proportion of women freezing their eggs – a rise from 4,700 in 2022 to 6,900 in 2023 – but the HFEA said that the number of patients using their stored frozen eggs in treatment remains "low.' Meanwhile the HFEA also said that in 2023, around 820 babies were born following donor insemination (DI) treatment. The figures also show a reduction in the number of IVF treatments funded by the NHS. The proportion of NHS-funded IVF cycles declined from 35% in 2019 to 27% in 2023. Racial disparities The HFEA also raised concerns about racial disparities in IVF. It said that in recent years, Asian and Black patients have had lower birth rates compared to white patients and those from a mixed ethnic background. Julia Chain, chairwoman of the HFEA, said: "IVF is helping more people have babies including patients of different ages and family types. "One in 32 of all British births are from IVF and 11% of all UK births are to women aged 40-44 who had IVF. "These findings highlight the changing landscape of the fertility sector and how it could develop in the years to come. "However, we are very concerned to see that Black and Asian patients continue to have lower IVF birth rates compared to other patient groups, and our recent survey found that Asian and Black patients are less likely to report being satisfied with their fertility treatment.' Data from the Office for National Statistics show that the fertility rate in England and Wales in 2023 was 1.44 children per woman – the lowest level on record. Commenting on the HFEA data, a spokesperson from the fertility charity Fertility Network UK said: "This important report from the HFEA reflects how essential fertility treatment has become for growing families and underlines not just the scientific advances in fertility care, but also the profound social impact of helping people realise their dreams of parenthood. "Delays in accessing treatment – whether due to long GP referral times or inconsistent NHS funding – can have a devastating emotional and biological impact. We call for fair and timely access to fertility services for all, wherever they live and whatever their background.' – dpa
Malaysian Reserve
4 days ago
- Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /CNW/ — USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cue Biopharma, Inc. (NASDAQ: CUE), Verastem, Inc. (NASDAQ: VSTM), Allogene Therapeutics, Inc. (NASDAQ: ALLO), and Perspective Therapeutics, Inc. (NYSE-American: CATX). While regulatory red tape tightens, surging diagnoses of colorectal and other GI cancers in young people demand quicker innovation in oncology. Forecasts suggest worldwide cancer‑drug revenues could blow past US$900 billion by 2034. Within that, next‑gen therapies built on precision techniques are slated to reach US$175.2 billion, advancing at a brisk 7.35% annual clip. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) recently held a well‑attended key opinion leader (KOL) webinar where pancreatic and gastrointestinal cancer specialists dissected pelareorep's clinical history, its biomarker data package, and where the oncolytic virus could slot into evolving chemotherapy and immunotherapy regimens. 'I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event,' said Jared Kelly, CEO of Oncolytics. 'Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers.' The panel revisited survival gains in metastatic pancreatic ductal adenocarcinoma (mPDAC), reviewed translational evidence of 'cold‑to‑hot' tumor conversion, and outlined next steps for a registration-enabling study. Management said feedback from the discussion would inform both upcoming trial designs and partnering talks now underway. The event came on the heels of Oncolytics having rolled out an expanded translational‑data review that tightened the scientific case for pelareorep, an intravenously delivered oncolytic reovirus. Renewed analyses from the GOBLET gastrointestinal cancer study and the AWARE‑1 breast cancer study confirmed that the virus replicates inside tumors, switches on interferon signaling in the immune system, and draws tumor‑infiltrating lymphocytes into the tumor microenvironment. 'This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action,' said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. 'We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.' Investigators also recorded higher PD‑L1 expression and tracked newly expanded cytotoxic T‑cell clones in blood samples that matched those inside shrinking lesions—molecular fingerprints that point to stronger responses when pelareorep is combined with standard-of-care treatments and checkpoint inhibitors. 'The collection of data here show that pelareorep works how a cancer immunotherapy should work,' said Jared Kelly, CEO of Oncolytics. 'Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs.' Clinical outcomes already hint at real‑world benefit. In more than 100 first‑line mPDAC patients, pelareorep‑based regimens achieved a 21.9% two‑year overall‑survival rate versus a 9.2% historical benchmark. A separate single‑arm study that paired pelareorep with chemotherapy and a checkpoint blocker produced a 62% objective‑response rate—especially notable given that no checkpoint therapy is approved in this cancer today. In hormone‑receptor‑positive, HER2‑negative metastatic breast cancer (HR+/HER2‑ mBC), two randomized trials added more than ten months of median overall survival, while BRACELET‑1 nearly doubled median progression‑free survival to 12.1 months compared with 6.4 months for control patients. To steer these data toward value‑creating deals and late‑stage trials, the company strengthened its leadership earlier this year by appointing industry veteran Jared Kelly as CEO and naming Andrew Aromando Chief Business Officer. The duo previously helped guide Ambrx Biopharma into a US$2 billion sale to Johnson & Johnson, experience the board believes will support capital‑efficient development and strategic partnering for pelareorep. 'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications,' said Kelly. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy.' As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. 'I'm thrilled to join Oncolytics at such a pivotal moment in its evolution,' said Aromando. 'With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term.' Pelareorep currently holds FDA Fast Track designations in mPDAC (pancreatic cancer) and HR+/HER2‑ mBC (breast cancer), along with Orphan‑Drug status for pancreatic cancer in the United States and Europe. With mechanistic proof, survival data that outperform historical controls, and fresh validation from the recent KOL event, Oncolytics Biotech is aligning its clinical, regulatory, and business strategies to move pelareorep into registration‑enabling trials and position it as a backbone immunotherapy across solid tumors. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Cue Biopharma, Inc. (NASDAQ: CUE) recently reported that adding CUE‑101 to pembrolizumab produced a 50% overall response rate in patients with recurrent/metastatic HPV‑positive head and neck cancer who had a combined positive score (CPS) ≥ 1, including the same 50% response in those with low CPS 1–19. The regimen has now generated two complete responses, an 88% 12‑month overall survival rate, and a median overall survival of 32 months, handily outperforming historical pembrolizumab data. 'The culmination of maturing data further support our conviction that CUE-101, representative of our approach with the CUE-100 series, demonstrates a potential breakthrough therapeutic approach for establishing a new standard of care,' said Dan Passeri, CEO of Cue Biopharma. 'With this maturing data, we are further emboldened in our conviction that our Immuno-STAT® platform represents transformative potential for selectively modulating the patient's immune system.' Verastem, Inc. (NASDAQ: VSTM) recently published Phase 2 RAMP 201 results in the Journal of Clinical Oncology, showing avutometinib + defactinib delivered a 31% confirmed overall response rate in recurrent low‑grade serous ovarian cancer, rising to 44% in KRAS‑mutant tumors. 'The publication of the primary analysis of the RAMP 201 study in recurrent low-grade serous ovarian cancer in the Journal of Clinical Oncology reflects the meaningful clinical advancement demonstrated by the combination of avutometinib plus defactinib for patients with recurrent low-grade serous ovarian cancer,' said John Hayslip, M.D., Chief Medical Officer at Verastem Oncology. 'The findings supported the recent FDA approval of the combination in KRAS-mutated recurrent low-grade serous ovarian cancer and our ongoing global Phase 3 RAMP 301 trial of the combination in recurrent low-grade serous ovarian cancer with and without a KRAS mutation.' Median progression‑free survival reached 12.9 months overall and 31.0 months in the KRAS‑mutant subgroup, with 82% of patients experiencing some tumor shrinkage regardless of mutation status. Back in June, Allogene Therapeutics, Inc. (NASDAQ: ALLO) presented updated Phase 1 TRAVERSE data showing a single dose of ALLO‑316 achieved a 31% confirmed response rate in heavily pre‑treated renal cell carcinoma patients whose tumors expressed CD70 in ≥ 50 % of cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' Four of five responders remain in remission—including one lasting more than 12 months—while safety remained manageable with no graft‑versus‑host disease observed. Investigators say the results highlight allogeneic CAR T's potential in solid tumors and justify continued expansion of the study. Perspective Therapeutics, Inc. (NYSE-American: CATX) recently began recruiting the third dose‑escalation cohort of its Phase 1/2a trial testing [²¹²Pb]VMT‑α‑NET in unresectable or metastatic somatostatin receptor 2 (SSTR2)‑positive neuroendocrine tumors, raising the fixed dose by 20% to 6 mCi. Earlier cohorts showed anti‑tumor activity with mostly low‑grade adverse events, prompting FDA alignment to explore whether the higher dose can further enhance efficacy. 'We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial,' commented Markus Puhlmann, Chief Medical Officer of Perspective. 'We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile.' The company plans additional safety and efficacy readouts, including dosimetry analyses, at scientific meetings in 2H 2025. Source: CONTACT:USA NEWS GROUPinfo@ 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo –
